News
BHVN
--
0.00%
--
DJ Biohaven Pharma Price Target Raised to $76.00/Share From $73.00 by Morgan Stanley
Dow Jones · 5h ago
DJ Biohaven Pharma Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 5h ago
Morgan Stanley Adjusts Price Target on Biohaven Pharmaceutical Holding to $76 From $73, Maintains Equal-Weight Rating
MT Newswires · 7h ago
Calcitonin Gene-Related Peptide Type 1 Receptor Market Size 2021 Research Report including Industry Segment by Type, Historical Data and Market Forecast to 2026
Apr 16, 2021 (The Expresswire) -- Final Report will add the analysis of the impact of COVID-19 on this industry. “Calcitonin Gene-Related Peptide Type 1...
The Express Wire · 3d ago
TENX: HELP Results & New Asset to Boot
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT
Benzinga · 5d ago
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
PR Newswire · 6d ago
Rett Syndrome Therapeutics Market Size, Analysis, Demand, Share, Growth Estimation, Developing Trends and Forecast 2021 to 2027
Apr 12, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Rett Syndrome Therapeutics Market”...
The Express Wire · 04/12 09:00
William Blair Keeps Their Buy Rating on Biohaven Pharmaceutical Holding Co (BHVN)
William Blair analyst Tim Lugo maintained a Buy rating on Biohaven Pharmaceutical Holding Co (BHVN) on April 7. The company's shares closed last Friday at
SmarterAnalyst · 04/09 17:45
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Stock Jumps 8.5%: Will It Continue to Soar?
Zacks.com · 04/09 03:06
Biohaven Crushes Forecasts; What's Next For Its Blockbuster Hopeful?
Investor's Business Daily · 04/07 21:10
Biohaven sees Q1 NURTEC ODT revenue of $44M, shares up 6%
Biohaven Pharmaceutical (BHVN) reports preliminary net product revenue for NURTEC ODT (rimegepant) of $43.8M for Q1 2021.Total prescriptions of NURTEC ODT from product launch to March 31, were over 500K,
Seekingalpha · 04/07 12:31
Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, today announced preliminary net product revenue of NURTEC ODT (rimegepant) ...
PR Newswire · 04/07 12:30
BRIEF-Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT
reuters.com · 04/07 11:36
Biohaven Pharma 1Q NURTEC ODT Preliminary Net Pdt Rev $43.8M >BHVN
Biohaven Pharma 1Q NURTEC ODT Preliminary Net Pdt Rev $43.8M >BHVN
Dow Jones · 04/07 11:31
Calcitonin Gene Related Peptide Type 1 Receptor Market Research Report by Type, by Product, by Application - Global Forecast to 2027 - Cumulative Impact of COVID-19
Apr 06, 2021 (Market Insight Reports) -- CANADA - QYResearchMedical recently added a research report, Calcitonin Gene Related Peptide Type 1 Receptor market...
Market Insight Reports · 04/06 19:39
8-K: Biohaven Pharmaceutical Holding Co Ltd.
(EDGAR Online via COMTEX) -- 0001689813FALSE00016898132021-03-312021-03-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/06 13:43
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members
, /PRNewswire/ -- Rick Ware Racing announced today its partnership with Biohaven's Nurtec® ODT (rimegepant) and Nine Line Apparel to honor the nation's fallen service members during the Memorial Day weekend Coca-Cola 600 at the Charlotte Motor Speedway. F...
PR Newswire - PRF · 04/06 11:30
The Biohaven Pharmaceutical Holding (NYSE:BHVN) Share Price Is Up 179% And Shareholders Are Boasting About It
Biohaven Pharmaceutical Holding Company Ltd. ( NYSE:BHVN ) shareholders might be concerned after seeing the share price...
Simply Wall St. · 04/02 06:40
Is BHVN Stock A Buy or Sell?
In this article you are going to find out whether hedge funds think Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock...
Insider Monkey · 03/29 20:01
Webull provides a variety of real-time BHVN stock news. You can receive the latest news about Biohaven Pharma through multiple platforms. This information may help you make smarter investment decisions.
About BHVN
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. The Company also develops bispecific compounds that is designed to emulate or enhance the activity of biologics.